Valneva Se · EURONEXT:VLA
Valneva — Investor Presentation (October 2026)
25 slides from Valneva's investor presentation, October 2026
Slide 1: A Leading Specialty Vaccine Company
A Leading Specialty Vaccine Company October 2026
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer Certain information and statements included in this presentation are not historical facts to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to but are for
Slide 3: A Leading Specialty Vaccine Company: Focused on vaccines that make a difference
Cash-Generating Specialty Vaccines Business: Proprietary travel vaccines: IXIARO®, DUKORAL®, IXCHIQ® A Leading Specialty Vaccine Company: Blockbuster Opportunity: Lyme disease vaccine partnered with Pfizer showed strong efficacy in Phase 3; Focused on vaccines that Regulatory submission validated by
Slide 4: Our Strategy as a Leading Vaccine Biotech Company
Our Strategy as a Leading Vaccine Biotech Company Contributing to a world in which no one dies or suffers from a vaccine preventable disease Fully Leverage … Maximize Integrated Biotech Drive R&D Upside Model Commercial Growth Augment clinical pipeline to achieve Create value with proven R&D Provide
Slide 5: Proprietary Commercial Portfolio of Differentiated Vaccines
Proprietary Commercial Portfolio of Differentiated Vaccines Differentiated vaccines Brand Indication Differentiation Key Markets Valneva direct markets: US, CA, UK, Only vaccine approved in U.S./Europe FR, Nordics, BE, NL, AT, ES, PT Active immunization against Japanese Requirement for U.S. military
Slide 6: Valneva's Current R&D Portfolio
Valneva’s Current R&D Portfolio Program Design/Description Pre-Clinical Phase 1 Phase 2 Phase 3 World’s most clinically advanced LB6V / VLA15: Lyme vaccine candidate; protein Lyme disease subunit-based Clinical VLA1553: Post-marketing efficacy studies Programs Chikungunya underway; live-attenuated v
Slide 7: LB6V / VLA15 World's leading Lyme Disease Vaccine Candidate
LB6V / VLA15 World’s leading Lyme Disease Vaccine Candidate
Slide 8: Lyme Disease Represents A Major Medical Need
Lyme Disease Represents A Major Medical Need No vaccine is currently available to prevent Lyme disease in humans Early Severe Persistent Manifestations Manifestations1 Symptoms2,3 Flu-like symptoms 10-30% cases develop: 5-10% cases continue • Carditis to have chronic symptoms Erythema migrans follow
Slide 9: Lyme Disease Prevention is a Major Global Market Opportunity
Lyme Disease Prevention is a Major Global Market Opportunity Annual reported cases likely underrepresent the burden of Lyme disease Substantial Populations of People Live in Annual Reported Cases1,2 High-Risk Areas for Lyme disease1,2 • U.S. : ~476K cases • Europe : >132K cases Epidemiological studi
Slide 10: Lyme Disease: a substantial economic burden
Lyme Disease: a substantial economic burden Prevention is critical to reduce both Lyme disease and its associated personal and societal costs United States: Annual Healthcare Cost of Lyme Disease Estimated at up to $1 Billion • Two studies1,2 estimate the annual cost of LD at up to $1B in the U.S. a
Slide 11: World's Leading Vaccine Candidate Against Lyme Disease
World’s Leading Vaccine Candidate Against Lyme Disease The only Lyme disease program in advanced clinical development today Vaccine Market Key Highlights Opportunity Milestones Multivalent, recombinant proteins Exclusive, worldwide Reported strong efficacy in partnership1 Phase 3 trial with no safet
Slide 12: Phase 3: Randomized Placebo-Controlled Field Efficacy Study
Phase 3: Randomized Placebo-Controlled Field Efficacy Study Tick Season 2023 Tick Season 2024 Tick Season 2025 VLA15 Cohort 1 Placebo Topline Month 0 2 5-9 6-10 13 18 19 25 Efficacy Primary series Booster Read-out VLA15 Cohort 2 Placebo Month 0 2 5-9 6-10 13 18 19 25 Primary series Booster Populatio
Slide 13: LB6V (formerly VLA15) Demonstrates Strong Efficacy in Phase 3
LB6V (formerly VLA15) Demonstrates Strong Efficacy in Phase 31 Results strengthen confidence – MAA validated by EMA2; regulatory decisions expected in the next 12 months3 Vaccine Efficacy Safety Pre-specified Analysis Vaccine candidate was well tolerated Efficacy (95% CI) (Season 2) From Day 28 post
Slide 14: LB6V is a Compelling Opportunity in an Underserved Market
LB6V is a Compelling Opportunity in an Underserved Market First-Mover Differentiated Compelling Strategic Fit Attractive Advantage in Highly Product Profile Target Population with Pfizer’s Vaccine Commercial Receptive Market and Use Case Franchise Dynamics Only Lyme disease Proven MoA with Broad add
Slide 15: IXCHIQ / VLA1553 A Highly Differentiated single-shot Chikungunya Vaccine
IXCHIQ® / VLA1553 A Highly Differentiated single-shot Chikungunya Vaccine
Slide 16: Chikungunya: A Major Public Health Threat
Chikungunya: A Major Public Health Threat Mosquito-transmitted outbreak disease with potentially debilitating consequences • Often causes large, explosive outbreaks • Affecting up to 75% of the local population1 • Substantial quality-of-life and health-economic impact2 • Nearly half (43%) of those i
Slide 17: IXCHIQ: Focused on Confirming Efficacy/Safety and Expanding Access
IXCHIQ®: Focused on Confirming Efficacy/Safety and Expanding Access Robust clinical program supported by CEPI grant Pilot Vaccination Campaign Ongoing (Brazil) To serve as the basis for post-marketing commitment studies • Launched in February 2026 with partner Instituto Butantan in select municipali
Slide 18: S4V2 World's Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
S4V2 World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
Slide 19: S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease
S4V2: Opportunity to Develop First-in-Class Vaccine for a Life-Threatening Disease Tetravalent bioconjugate vaccine with potential to cover up to ~85% of shigellosis infections1 Vaccine Market Key Highlights Opportunity Milestones World’s most clinically advanced Global market expected to exceed Pha
Slide 20: Commercial Assessment of Shigella Vaccine
Commercial Assessment of Shigella Vaccine Shigella vaccine market estimated to peak at ~€500 million1 Children in endemic Traveler (~23%) Military (<1%) countries (~76%) 20-50% 30-100% 70-90% Recommendation (OOP-reimbursement) (Med-high risk destinations) (Med-high risk destinations Acceptance 30% 1
Slide 21: Financial Guidance & Outlook
Financial Guidance & Outlook
Slide 22: Vaccine Sales Fuel Strategic Investments into R&D
Vaccine Sales Fuel Strategic Investments into R&D Focus on proprietary vaccines expected to drive revenue quality, margin expansion with strategic reduction in third-party product (3PP) sales1 Lean and Efficient € 163m € 135m – € 150m2 Commercial Infrastructure € 158m IXCHIQ® Highly experienced team
Slide 23: Financial Outlook
Financial Outlook 2026 Sales Guidance Financial Outlook Product Sales: €135 - €150 million (reiterated); Continued cash flows from proprietary Commercial business expected to remain cash- commercialized vaccines flow positive Restructuring program implemented with positive P&L and cash flow impacts
Slide 24: Our Next Phase as a Leading Vaccine Biotech Company
Our Next Phase as a Leading Vaccine Biotech Company Potential LB6V Success Would Offer Strategic Growth Opportunities Leverage core strengths in vaccine development to deliver greater long-term value Key initiatives: Build scale in R&D pipeline post-LB6V exit • Strategic in-licensing/M&A to augment
Slide 25: Thank you
Thank you Merci Danke Tack valneva